Lunit vs Oatmeal Health
Both work lung cancer screening and only one of them reads the image. Lunit builds the detection capability across chest radiograph and mammography, with a deep evidence base in screening populations and regulatory footprints in several markets. Oatmeal builds the programme, running lung cancer screening in federally qualified health centres where the eligible population is large, capacity is thin and the failure is almost never identification but navigation and follow through. A safety net organisation trying to move its screening rate needs both, and buying only the algorithm will not move it at all. Ask any screening programme for its rates by race and insurance status, because an intervention that lifts the average while widening the gap has not helped.
- Cancer detection across chest radiograph and mammography is the portfolio, with a listed parent and regulatory footprints in multiple markets.
- The evidence base in screening populations is deeper than most detection vendors, which is the setting where both sensitivity and specificity bite.
- For a screening programme, a vendor built around cancer detection is a closer fit than a general findings reader.
- It targets lung cancer screening in federally qualified health centres, where uptake is lowest and the eligible population is largest relative to capacity.
- Screening in that setting fails on navigation and follow through rather than identification, and the product is built around that reality.
- Focusing on one cancer in one setting makes the economics legible in a way a multi condition programme is not.
Side by Side
| Axis | L Lunit |
O Oatmeal Health |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These are complementary rather than competing: one supplies the reading capability and the other supplies the programme around it, and a safety net organisation needs both to move a screening rate. Lung cancer screening carries a documented equity gap in both eligibility criteria and uptake, so any programme should report screening and follow through rates by race and insurance status rather than in aggregate, since an intervention that lifts the average while widening the gap has not helped the people it was sold to reach. Neither publishes pricing.